Please wait while the transcript is being prepared...
0:00
Hi, I'm Dr. Randall Brand.
I'm Professor of Medicine
at the University
of Pittsburgh Medical Center
in the Division of Gastroenterology,
Hepatology and Nutrition.
It's my pleasure to discuss
with you today
on the topic of pancreatic cancer.
0:17
My talk today will review some general
background on pancreatic cancer,
highlighting risk factors
for the disease,
how it clinically presents,
some of the common diagnostic modalities
used in pancreatic cancer,
review pancreatic cystic lesions,
the staging of the disease, treatment,
and then some of our current needs
for the disease.
0:45
Worldwide pancreatic cancer
causes over 300,000 deaths.
In the United States,
it's estimated that there will be
over 53,000 new patients
diagnosed with pancreatic cancer,
with majority of these dying
with a predicted almost 42,000 deaths.
In the United States,
there's about 1.4% lifetime risk
of developing pancreatic cancer,
and it's currently
the third leading cause
of cancer-related mortality
in the United States.
The vast majority of the tumors
are adenocarcinomas
accounting for over 90% with other types
including neuroendocrine,
acinar, and lymphomas.
My talk today will be focusing
on adenocarcinomas.
1:35
As you can see here,
this is a diagram showing
five-year survival rates
for major digestive diseases.
This is colon cancer where we've had
significant improvement since 1975
with rates increasing almost 20%.
This is pancreatic cancer,
and you can see since 1975
that we've only made modest gains,
and we're still under 10%
for five-year survival.
This is compared to several
of the other GI malignancies
where they despite still four
or five-year survival rates,
they're getting closer to 20%.
